Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer

Overview of attention for article published in Core Evidence, April 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)

Mentioned by

patent: 3 patents

wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 66 Mendeley

Summary Patents Wikipedia Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Grant US-RE49353-E1

United States of America

Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Grant US-11491149-B2

United States of America

ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER

Grant EP-3305285-B1

European Patent Office